Antigen-Specific Immunotherapy Using Lentivirus-Transduced Hematopoietic Progenitor Cell: A Novel Approach for the Treatment of Metastatis Prostate Cancer
Abstract
This group has completed the goal set for Task 1 ("To examine the immune responses to a model tumor antigen selectively expressed in DCs differentiated in vivo from transduced hematopoietic progenitor cells"). They have: 1) made lentiviral vectors expressing a model tumor antigen influenza hemagglutinin (HA); 2) developed a method to efficiently transduce mouse bone marrow progenitor cells that reconstitute immune and blood systems in irradiated and transplanted mice; 3) demonstrated that the transplanted and transduced cells can persistently present the HA model tumor antigen and stimulate T cell responses; 4) devised a tripartite strategies to mount powerful and specific attack on HA-expressing experimental tumors; and 5) demonstrated the efficacy to eradicate an aggressive pre-established tumor expressing the HA antigen. This study provides a proof-of-principle in immune competent animals models that transplantation of antigen gene transduced hematopoietic progenitor cells adds a new component to achieve potent and sustained antigen-specific immunotherapy of aggressive tumors. Key discoveries by this group and their Hopkins colleagues were published in a leading biomedical research journal Nature Medicine (10: 882).
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2004
- Accession Number
- ADA423340
Entities
People
- Linzhao Cheng
Organizations
- Johns Hopkins University